Jersey Shore NJ

Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic...

The Press of Atlantic City

Oct 12, 2019

PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic,…

Read the full story at The Press of Atlantic City

Related places

Atlantic City

Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic...

Related places

More from Jersey Shore

Middle Twp. Police Officer Hit by Suspected Drunk Driver

10 Years Later: Will We Ever See Another Desert Trip?

Only 16 Atlantic City Police Officers In 156 Years Have Done This

Toms River Halloween Parade Has International Appeal

East Gate Homeowners Face $20K Bill for JCP&L Connection

Monmouth Council Honors Red Bank Building's Ties to Scouting History

Red Bank Catholic Survives Rumson-Fair Haven Comeback Bid to Clinch Championship

County Towns Receive $9.15M in Open Space Grants